Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telisotuzumab Adizutecan vs Standard of Care in Previously Treated EGFR Wildtype Non-Squamous NSCLC
NCT07821684Phase 3Not yet recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jan 2027
- Primary completion
- Mar 2030
01
Overview
A Phase 3 trial of telisotuzumab adizutecan in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by AbbVie Inc.. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
telisotuzumab adizutecan
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT07821684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07821684.